ClinicalTrials.gg
RecruitingNCT07478289OPTIMALUpdated Mar 17, 2026

A Phase II Trial Evaluating Radiation Boost to Painful Spinal Metastases

A Phase 2 interventional study of Radiation Boost in Spine Metastasis, sponsored by Sunnybrook Health Sciences Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Sunnybrook Health Sciences Centre · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Neoplasm Metastasis with a site in Canada — 58 open to participants now, 116 under way, 39 of them phase 3. Neoplasm Metastasis · Canada.

Planned enrollment
187th of 323
108 · median 152
Started
2026
with 9 others
Phase 2
84 of 353
6 open now
Primary completion
2029-12
later than 100 of 115 live
Registered
350th of 353
by date

Among the 353 studies in Neoplasm Metastasis with a site in Canada, this one is the 187th largest by planned enrollment of the 323 interventional ones that give a count, is one of 10 that started in 2026, is one of 84 in phase 2, reaches primary completion later than 100 of the 115 other live ones, and was the 350th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

58 of the 353 studies in Neoplasm Metastasis with a site in Canada are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Neoplasm Metastasis with a site in Canada, or all of them as a file.
02

Study summary

Spine SBRT is considered a standard of care for the treatment of spinal metastases. Compared to conventional radiation therapy, spine SBRT delivers high doses of radiation to the affected areas to the spinal metastases.

This study is interested in seeing whether an additional 'boost' of radiation, delivered to the affected area in the spine, will result in better long-term control of the tumor; help reduce pain; and reduce long-term side effects of radiation therapy.

03

Conditions studied

  • Spine Metastasis

Browse trials for

Keywords

  • spinal metastases
  • SBRT
  • Simultaneous Integrated Boost
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathologically confirmed solid tumor , or strong suspicion based on clinical and radiographic examination of malignancy
  • Spinal with paraspinal disease extension documented with MRI and recommended for treatment with SBRT
  • Post-operative SBRT is permitted (after stabilization and/or decompression surgery) as long as no prior radiotherapy had been delivered to the spinal level planned for trial treatment and paraspinal disease is present
  • performance status 0-2
  • Able to tolerate protocol SBRT
  • Age 18 years or older
  • Patient is able and willing to complete the Patient Diary (pain and analgesic use)
  • Consent must be appropriately obtained in accordance with local requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
  • Patients must be accessible for treatment and follow-up
  • Treatment to begin within 14 days (ideally 7 days) of radiotherapy simulation

Exclusion criteria

Exclusion Criteria:

  • Extremely radiosensitive histology (seminoma, small cell lung cancer, hematologic primaries)
  • Prior radiotherapy in the spine target of interest
  • Spinal instability as assessed by the Spinal Instability Neoplastic Score with a score of > 12
  • Symptomatic cord compression or cauda equine syndrome resulting from bony compression or epidural compression of the spinal cord and cauda equina, respectively. Symptomatic refers to neurologic deficit in the form of motor, bowel or bladder dysfunction
  • Pacemaker, such that MRI cannot be performed or treatment cannot be delivered safely
  • Cytotoxic chemotherapy within 1 week prior to radiotherapy delivery
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Radiation Boost

    Participants would receive a radiation boost to their spinal metastases (as described in "Intervention")

    Radiation: Radiation Boost

Interventions

  • RadiationRadiation Boost

    An additional boost of radiation will be delivered to the spinal metastases. The amount of boost depends on how much radiation would have been normally prescribed (e.g., if treatment required 2 fractions of radiation treatment, an additional 2 Gy would be prescribed; if treatment required 4 fractions of radiation treatment, an additional 4 Gy would be prescribed; if treatment required 5 fractions of radiation treatment, an additional 5 Gy would be prescribed).

06

What researchers measure

Primary outcomes

  1. Disease Progression within the Treated Spinal Metastasis, in accordance with SPINO (SPIne assessment in Neuro-Oncology) guidelines

    Time frame: Up to 12 months after completion of radiation therapy

Secondary outcomes

  1. Pain at treated spinal metastases, per ICPRE (International Consensus on Palliative Radiotherapy Endpoints)

    Time frame: 3 and 6 months following completion of radiation therapy

  2. Type of progression

    Whether the progression occurred at local, marginal, or distant location

    Time frame: Up to 12 months after completion of radiation therapy

  3. Treatment-related side effects as assessed by CTCAE v5.0

    Time frame: Up to 12 months following completion of radiation therapy

  4. Spinal Instability, as assessed through the Spinal Instability Neoplastic Scores (SINS)

    Time frame: Up to 12 months following completion of radiation therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2029, 44 months later.

Of 354 non-industry phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 90. This study's planned 44 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartEst.
Apr 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2031
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478289
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2029 (estimated)
Completion
Dec 2031 (estimated)
Last update
Mar 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion